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Margaret Chisolm:  It’s accepted that pregnancy is a win-
dow of opportunity when women are highly motivated to 
make behavioral changes. There’s a higher spontaneous 
quit rate among pregnant smokers than in the general 
population of smokers.
Most of  the women in our program are extremely 
motivated for treatment. In part, primarily, they are 
concerned about the fetus. Those who are abusing 
illegal substances also know that they might lose cus-
tody of their child if they continue to do so during 
their pregnancy.
Victoria Coleman-Cowger:  I understand why some 
States want to protect children from the lifestyles of drug-
abusing parents. At the same time, the policy becomes a 
barrier to women getting treatment and receiving other 
needed services as well as to participating in research 
studies focused on this population. Women are less 
likely to disclose drug abuse if they know it means that 
their children might be taken away. 
Chisolm:  Most of the women we treat at the Johns 
Hopkins Center for Addiction and Pregnancy use illicit 
opioids. When I arrived, I was struck by how many of 
them smoked. That raised questions for me. What was 
the relative risk of smoking versus the other dependencies 
we were treating? Did smoking make it more difficult for 
them to stop using other substances? Conversely, would 
smoking cessation jeopardize their recovery? 
Coleman-Cowger:  As a Research Scientist at Chestnut 
Health Systems, I recognize how difficult it is to study 
these issues. For longitudinal studies, researchers need 
to recruit large numbers of mothers and children so 
that they can control for all the potential influences on 
outcomes. Then they need to follow the participants for 
years or decades to see what outcomes occur.
Both requirements are harder when you’re talking 
about illegal substances and lives that may be chaotic. 
We know more about prenatal tobacco and alcohol 
exposure than about other prenatal exposures in part 
because women don’t face legal consequences if they 
acknowledge that they smoke or drink.
Chisolm:  It’s because of those difficulties that I’m not 
yet convinced that prenatal exposures cause all the behav-
ioral problems with which studies associate them. For 
example, a high percentage of women in our program had 
ADHD diagnosed when they were children themselves. 
To me, that suggests that genes, rather than drugs, may 
be at least part of the reason why their children tend to 
have behavioral problems. The challenge of establishing 
causal relationships with prenatal exposures increases as 
children get older and accumulate more environmental 
exposures and begin to express genetic vulnerabilities 
that might influence their behavior.
So we tell women that it’s better not to smoke or use 
other drugs during pregnancy. We know that avoiding 
substances will give them better birth outcomes, because 
the evidence is conclusive that drug exposures cause 
pregnancy complications and neonatal morbidity and 
mortality. But we don’t say that smoking is going to 
increase their children’s risk of ADHD or anything like 
that. I think the evidence is less compelling for those 
more distal outcomes.
Treatment motivation and interventions
Coleman-Cowger:  Contingency management (CM) 
has been shown to very effectively reduce drug use. I’m 
planning to use it with pregnant and postpartum smokers 
in a pilot study of postpartum continuing care, giving 
Babies R Us gift cards in escalating amounts for each 
successive negative urine test.
Chisolm:   There is a lot of potential with CM to improve 
outcomes and to save health costs. CM economics   
probably work best for comprehensive health systems. 
Although the CM vouchers cost their substance abuse 
treatment components, their other components save by 
having to treat fewer or less serious health consequences of 
abuse. A stand-alone substance abuse program, however, 
might lay out for the vouchers but not get any savings 
down the line.
 
Coleman-Cowger:  I don’t believe there have been 
many studies of CM with long-term followup. I’ve seen 
studies in which some effects have been sustained after 
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3 months, but none looking at outcomes for longer 
periods of time.
Chisolm:  I don’t consider myself an expert in CM, but 
the evidence suggests that as soon as you stop the rein-
forcement, the behavior reverts to what it was before. 
For example, a study here at Johns Hopkins gave contin-
gency rewards to promote abstinence among post partum 
women who had been heavy users of cocaine during their 
pregnancies. The women maintained close to 80 percent  
abstinence throughout the 18 months that the rewards 
were being given, but the rate fell to around 20 percent 
within a few months after the rewards were stopped.
We have just finished a study in which we measured 
drug-dependent mothers’ carbon monoxide levels on 
breathalyzer tests. We are looking to see whether giv-
ing these mothers feedback on these results might be 
a powerful reinforcer for reducing smoking, as it is in 
non-drug-dependent pregnant women. If so, that would 
be a good low-cost approach to promote abstinence 
during pregnancy in this population, too.
Coleman-Cowger: Dr. Minnes’ endorsement of nicotine 
replacement therapy (NRT) for pregnant women who 
are heavy smokers is in line with the recommendation of 
the American College of Obstetricians and Gynecologists 
that pharmacological agents be considered when a preg-
nant woman is otherwise unable to quit smoking. The 
efficacy studies that have been completed so far haven’t 
proved that NRT makes a difference in cessation rates 
for pregnant women. However, the results have been 
mixed and more favorable with respect to reducing use.
Chisolm: That’s right. One of the studies that was halted 
because cessation rates didn’t improve actually showed 
reductions in the number of cigarettes per day. Neonatal 
outcomes improved as well.
NRT helps nonpregnant women quit smoking. 
Pregnant women might require higher doses than were 
used in these trials, since they metabolize the drug twice 
as fast. However, nobody really wants to give pregnant 
women higher doses of nicotine since it’s a known neu-
roteratogen.
As Dr. Minnes notes, bupropion is a category C drug, 
meaning that it has produced some evidence of fetal 
harm in animal studies and may pose a risk in humans. 
However, I’ve talked to many obstetricians and providers 
who use bupropion off-label as an alternative to NRT 
for their pregnant patients. This medication has proven 
efficacy for smoking cessation and as an antidepres-
sant, and perhaps could be the medication of choice 
for depressed pregnant women who smoke. Certainly, 
more investigation is warranted. 
Coleman-Cowger:  Postpartum continuing care is impor-
tant. Having a newborn is a very high stress time and 
one of the biggest times of risk for use of any substance. 
Without continuing to support women as intensively 
as they were supported during pregnancy, interventions 
would be very unlikely to have a sustained effect.
Some 80 percent of women who quit smoking dur-
ing pregnancy relapse within the first year after they’ve 
given birth. That’s unfortunate for both the woman and 
her infant, because nicotine is transmitted indirectly at 
very high rates in mothers’ milk, and directly through 
second-hand smoke, producing adverse outcomes.
   
Chisolm:  Substance-using pregnant women have a high 
incidence of comorbid mood and anxiety disorders. Up 
to 50 percent of the women in our program have a DSM-
diagnosable mood and/or anxiety disorder. Unless they 
get intensive treatment for these disorders postpartum, 
they are ripe for relapse.
Coleman-Cowger:  Partner interventions are an important 
component of care with a substance-using population, 
particularly with smokers, due to the likelihood that the 
partner may also be engaging in substance use or other 
enabling behaviors that could trigger relapse. The lack 
of focus on partners in the existing literature might be 
one reason why the interventions Dr. Minnes reports 
weren’t more efficacious.
Chisolm:  Pregnant women’s smoking is still not usu-
ally a targeted problem in drug abuse treatment, even 
though the links to significant adverse consequences 
for the mother and child are very clear. It’s not unusual 
for staff to be less interested in addressing tobacco use 
among their patients because a number of staff may be 
in recovery and smoke themselves, or are sympathetic 
to smoking. This is a situation in which we really need 
to address staff attitudes.    